A comparison of hepatopathologists' and community pathologists' review of liver biopsy specimens from patients with hepatitis C
- PMID: 19138761
- PMCID: PMC4603363
- DOI: 10.1016/j.cgh.2008.11.029
A comparison of hepatopathologists' and community pathologists' review of liver biopsy specimens from patients with hepatitis C
Abstract
Background & aims: Assessment of liver histology has an important role in the management of chronic liver disease. It is not clear whether there are interobserver variabilities between hepatopathologists and general community pathologists. We evaluated the effect of type of pathologist and biopsy specimen size on interobserver agreement for hepatic fibrosis.
Methods: Subjects were identified from a population-based sample of adults from a chronic liver disease surveillance network. Biopsy slides from 391 hepatitis C patients who had undergone liver biopsy were obtained and read by 2 study hepatopathologists blinded to the patients' diagnoses (the gold standard). The interobserver agreement of the fibrosis stage between the hepatopathologists and the general pathologists' report were evaluated by kappa index.
Results: There was complete agreement between the study pathologist and community pathologist in 49.9% of biopsy specimens. The overall kappa index across all stages of fibrosis was 0.409, with the best agreement occurring at higher stages of fibrosis (kappa: 0.482 for stage 3, 0.776 for stage 4). Overall agreement was good (kappa, 0.465) when biopsy samples were greater than 1.5 cm in size. The community pathologist understaged fibrosis in 73% of biopsy specimens with disagreement. A total of 26% of patients with stages 2 to 4 fibrosis were understaged by the community pathologist.
Conclusions: Results from this population-based study show good overall interobserver agreement between hepatopathologists and general pathologists when determining fibrosis stage in liver biopsy specimens from hepatitis C patients when liver biopsy sizes are adequate. However, community pathologists tended to understage fibrosis, which could keep patients from receiving proper treatment.
Conflict of interest statement
Conflicts of interest
The authors disclose no conflicts.
Similar articles
-
Intermediate fibrosis staging in hepatitis C: a problem not overcome by optimal samples or pathologists' expertise.Ann Hepatol. 2015 Sep-Oct;14(5):652-7. Ann Hepatol. 2015. PMID: 26256893
-
Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.Hepatology. 2010 Feb;51(2):585-94. doi: 10.1002/hep.23315. Hepatology. 2010. PMID: 20101752 Free PMC article. Clinical Trial.
-
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection.Am J Gastroenterol. 2002 Oct;97(10):2614-8. doi: 10.1111/j.1572-0241.2002.06038.x. Am J Gastroenterol. 2002. PMID: 12385448
-
Chronic viral hepatitis: the histology report.Dig Liver Dis. 2011 Mar;43 Suppl 4:S331-43. doi: 10.1016/S1590-8658(11)60589-6. Dig Liver Dis. 2011. PMID: 21459339
-
Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment.Liver Int. 2015 Apr;35(4):1103-15. doi: 10.1111/liv.12628. Epub 2014 Jul 19. Liver Int. 2015. PMID: 24976523 Review.
Cited by
-
Ultrasomics prediction for cytokeratin 19 expression in hepatocellular carcinoma: A multicenter study.Front Oncol. 2022 Sep 2;12:994456. doi: 10.3389/fonc.2022.994456. eCollection 2022. Front Oncol. 2022. PMID: 36119507 Free PMC article.
-
Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B.JHEP Rep. 2021 Sep 16;3(6):100364. doi: 10.1016/j.jhepr.2021.100364. eCollection 2021 Dec. JHEP Rep. 2021. PMID: 34712933 Free PMC article.
-
An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation.Radiol Oncol. 2021 Jan 29;55(2):130-143. doi: 10.2478/raon-2021-0004. Radiol Oncol. 2021. PMID: 33544992 Free PMC article. Review.
-
A large-scale internal validation study of unsupervised virtual trichrome staining technologies on nonalcoholic steatohepatitis liver biopsies.Mod Pathol. 2021 Apr;34(4):808-822. doi: 10.1038/s41379-020-00718-1. Epub 2020 Dec 9. Mod Pathol. 2021. PMID: 33299110 Free PMC article.
-
Liver cT1 decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus.Abdom Radiol (NY). 2021 May;46(5):1947-1957. doi: 10.1007/s00261-020-02860-5. Epub 2020 Nov 28. Abdom Radiol (NY). 2021. PMID: 33247768 Free PMC article.
References
-
- Seeff LB, Hoofnagle JH. National Institutes of Health consensus development conference statement: management of hepatitis C: 2002—June 10–12, 2002. Hepatology. 2002;36:S1–S20. - PubMed
-
- Manns MP, McHutchison J, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C; a randomised controlled trial. Lancet. 2001;358:958–965. - PubMed
-
- Fried MW, Shirrman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. - PubMed
-
- Hadziyannis S, Sette H, Morgan TR, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med. 2004;140:346–355. - PubMed
-
- Holund B, Poulsen H, Schlichting P. Reproducibility of liver biopsy diagnosis in relation to the size of the specimen. Scand J Gastroenterol. 1980;15:329–335. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
